Trastuzumab derukstekan - przełom w leczeniu raka piersi
Słowa kluczowe:
rak piersi, trastuzumab deruxtecanStreszczenie
Rak piersi jest najczęstszym nowotworem złośliwym na świecie i stanowi przyczynę 7% zgonów z powodu chorób nowotworowych na świecie. W obliczu tego wysiłek naukowców ukierunkowany jest na poszukiwanie nowych, skuteczniejszych leków znajdujących zastosowanie w terapii raka piersi. Wśród chorych na raka piersi szczególną grupę stanowią pacjentki z przerzutowym rakiem piersi o statusie receptorów HER2- low (niska ekspresja receptora HER2). Dotychczas chore te były traktowane tak samo jak pacjentki o statusie HER2 ujemnym i nie otrzymywały terapii celowanej anty-HER2. Wprowadzenie trastuzumabu derukstekanu do terapii w tej grupie pacjentek drastycznie odmieniło rokowanie i dało nadzieję na wydłużenie mediany czasu wolnego od progresji choroby (mPFS) oraz mediany całkowitego przeżycia (mOS).
Bibliografia
Hulvat MC. Cancer incidence and trends. Surg Clin North Am. 2020;100(3):469-481. doi:10.1016/j.suc.2020.01.002
Sung H, Ferlay J, Siegel RL i in. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. 2021;71(3):209-249. doi:10.3322/caac.21660
Gucalp A, Traina TA, Eisner JR i in. Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res Treat. 2018;173(1):37-48. doi:10.1007/s10549-018-4921-9
Radecka B, Litwiniuk M. Breast cancer in young women. Ginekol Polska. 2016;87(9):659-663. doi:10.5603/gp.2016.0062
Hankey BF. State bite age distribution of breast cancer cases. JNCI J National Cancer Inst. 1994;86(19):1441. doi:10.1093/jnci/86.19.1441
Ribnikar D, Ribeiro JM, Pinto D i in. Breast cancer under age 40: a different approach. Curr Treat Options Oncol. 2015;16(4). doi:10.1007/s11864-015-0334-8
Bennett LM. Breast cancer: genetic predisposition and exposure to radiation. Mol Carcinog. 1999;26(3):143-149. doi:10.1002/(sici)1098-2744(199911)26:3%3C143::aid-mc2%3E3.0.co;2-s
Ford D, Easton DF, Stratton M i in. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998;62(3):676-689. doi:10.1086/301749
Jerzak KJ, Mancuso T, Eisen A. Ataxia–telangiectasia gene (ATM) mutation heterozygosity in breast cancer: a narrative review. Curr Oncol. 2018;25(2):176. doi:10.3747/co.25.3707
Kaur RP, Vasudeva K, Kumar R, Munshi A. Role of p53 gene in breast cancer: focus on mutation spectrum and therapeutic strategies. Curr Pharm Des. 2018;24(30):3566-3575. doi:10.2174/1381612824666180926095709
Varna M, Bousquet G, Plassa LF, Bertheau P, Janin A. TP53 status and response to treatment in breast cancers. J Biomed Biotechnol. 2011;2011:1-9. doi:10.1155/2011/284584
Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13(11):1141-1151. doi:10.1016/s1470-2045(12)70425-42012;13(11):1141-1151. doi:10.1016/s1470-2045(12)70425-4
Rosato V, Bosetti C, Negri E i in. Reproductive and hormonal factors, family history, and breast cancer according to the hormonal receptor status. Eur J Cancer Prev. 2014;23(5):412-417. doi:10.1097/cej.0b013e3283639f7a
Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiologic Rev. 1993;15(1):36-47. doi:10.1093/oxfordjournals.epirev.a036115
Kanadys W, Barańska A, Malm M i in. Use of oral contraceptives as a potential risk factor for breast cancer: a systematic review and meta-analysis of case-control studies up to 2010. Int J Environ Res Public Health. 2021;18(9):4638. doi:10.3390/ijerph18094638
Marsden J, Pedder H. HRT and breast cancer risk – Fast facts. Post Reprod Health. 2021;27(1):42-44. doi:10.1177/2053369120973424
Sun YS, Zhao Z, Yang ZN i in. Risk factors and preventions of breast cancer. Int J Biol Sci. 2017;13(11):1387-1397. doi:10.7150/ijbs.21635
Freudenheim JL. Alcohol's effects on breast cancer in women. Alcohol Res. 2020;40(2). doi:10.35946/arcr.v40.2.11
Romieu I, Scoccianti C, Chajès V i in. Alcohol intake and breast cancer in the European prospective investigation into cancer and nutrition. Int J Cancer. 2015;137(8):1921-1930. doi:10.1002/ijc.29469
Kolak A, Kamińska M, Sygit K i in. Primary and secondary prevention of breast cancer. Ann Agric Environ Med. 2017;24(4):549-553. doi:10.26444/aaem/75943
Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Investig. 2017;127(1):1-4. doi:10.1172/jci92035
Hopkins BD, Goncalves MD, Cantley LC. Obesity and cancer mechanisms: cancer metabolism. J Clin Oncol. 2016;34(35):4277-4283. doi:10.1200/jco.2016.67.9712
Waks AG, Winer EP. Breast cancer treatment. JAMA. 2019;321(3):288. doi:10.1001/jama.2018.19323
Maughan KL, Lutterbie MA, Ham PS. Treatment of breast cancer. Am Fam Physician. 2010;81(11):1339-1346.
Shien T, Iwata H. Adjuvant and neoadjuvant therapy for breast cancer. JPN J Clin Oncol. 2020;50(3):225-229. doi:10.1093/jjco/hyz213
Prat A, Pineda E, Adamo B i in. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24:S26—S35. doi:10.1016/j.breast.2015.07.008
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the st gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011;22(8):1736-1747. doi:10.1093/annonc/mdr304
Narayan P, Osgood CL, Singh H, et al. FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer. Clinical Cancer Research. 2021;27(16):4478-4485. doi:10.1158/1078-0432.CCR-20-4557
Keam SJ. Trastuzumab deruxtecan: first approval. Drugs. 2020;80(5):501-508. doi:10.1007/s40265-020-01281-4
Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(1). doi:10.1038/s41392-022-00947-7
Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 2007;18(6):977-984. doi:10.1093/annonc/mdl475
Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The latest research and development into the antibody–drug conjugate, [fam-] trastuzumab deruxtecan (ds-8201a), for HER2 cancer therapy. Chem Pharm Bull. 2019;67(3):173-185. doi:10.1248/cpb.c18-00744
Yamato M, Hasegawa J, Maejima T i in. DS-7300a, a DNA topoisomerase I inhibitor, dxd-based antibody–drug conjugate targeting B7-H3, exerts potent antitumor activities in preclinical models. Mol Cancer Ther. 2022;21(4):635-646. doi:10.1158/1535-7163.mct-21-0554
Fehrenbacher L, Cecchini RS, Geyer Jr CE i in. NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2+. J Clin Oncol. 2020;38(5):444-453. doi:10.1200/jco.19.01455
Tarantino P, Hamilton E, Tolaney SM i in. HER2-Low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020;38(17):1951-1962. doi:10.1200/jco.19.02488
T-DXd: new standard for her2-low breast cancer. Cancer Discov. 2022:OF1. doi:10.1158/2159-8290.cd-nb2022-0043
Modi S, Jacot W, Yamashita T i in. Trastuzumab deruxtecan in previously treated her2-low advanced breast cancer. New Engl J Med. 2022. doi:10.1056/nejmoa2203690
Opublikowane
7 czerwca 2023
Prawa autorskie (c) 2023 Jacek Wysoczański, Antoni Anczyk, Karolina Handzel, Zuzanna Witkowska, Jakub Ciesielka, Radosław Dutczak
Licencja
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
